Multi-country

The Biomarker Test Cannot Wait Until Relapse

Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

When the Test Says Normal but the Pain Does Not

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

A Rare Childhood Ataxia Gets Real Phase III Evidence

Before a TB Vaccine Exists, Africa Is Building the Route to People

Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?

MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
